Novartis Korea Launches Domestic Phase 3 Clinical Trial of Aliskiren

Novartis Korea announced on December 9th that the international Phase 3 clinical trial of its anti-hypertension drug Aliskiren (SPP100), a renin inhibitor, will also take place in Korea along with four other countries.

According to Novartis Korea, Aliskiren (SPP100) is the first orally active renin inhibitor for treatment of hypertension, where Aliskiren reduces angiotensin II levels by dire...